Altered plasma drug binding in cancer: role of alpha 1-acid glycoprotein and albumin.
Altered concentrations of serum proteins often accompany malignant disease. The effect of these changes on drug binding was studied with lidocaine, a basic drug, and tolbutamide, an acidic drug. Patients with cancer had increased serum concentrations of the acute-phase protein alpha 1-acid glycoprotein (AAG) and lowered serum concentration of albumin. In association with these changes lidocaine binding was increased at all concentrations studied (predialysis concentrations 2, 6, and 10 microgram . ml-1) and that of tolbutamide was decreased at the highest concentration (200 microgram . ml-1). Not all of the increase in lidocaine binding was explicable on the basis of increased serum AAG concentration. Estimation of binding parameters with a model with two independent sites showed increased affinity at the high affinity site in cancer patients with no change in the calculated number of binding sites. Therefore, in cancer there is increased lidocaine binding in association with increased AAG concentrations. We also record the novel observation of a change in the intrinsic properties of the high affinity binding site.
D005260:Female; D006801:Humans; D008012:Lidocaine / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000378:metabolism; D009961:Orosomucoid / Q000378:metabolism*; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism*; D014044:Tolbutamide / Q000097:blood / Q000378:metabolism
D009961:Orosomucoid; D004364:Pharmaceutical Preparations; D012709:Serum Albumin; D014044:Tolbutamide; D008012:Lidocaine